BioInvent Interim Report 1 January – 30 September 2016

Important progress achieved in BioInvent’s immunotherapeutic programmes

LUND, Sweden--(BUSINESS WIRE)--Regulatory News:

BioInvent (STO:BINV)

Third quarter 2016, July - September
MORE ON THIS TOPIC